– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer expected to initiate by the end of 2022 – – MARIO-P, a study designed to expand ...
– Infinity Previously Announced Definitive Merger Agreement with MEI Pharma to Advance Three Promising Clinical Oncology Candidates – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. ...
–Updated TNBC data from MARIO-3 to be reported mid-year and 4Q’21– –Update for eganelisib in PD-L1 low, 2L advanced UC patients expected mid-year– –$92M public offering strengthens balance sheet for ...
Total loans were $223.7 million as of March 31, 2026, compared to $229.8 million for the fourth quarter of 2025, a decrease of $6.1 million, or (2.6%). When compared to the first quarter of 2025, ...
– Infinity Previously Announced Definitive Merger Agreement with MEI Pharma to Advance Three Promising Clinical Oncology Candidates – Research and development expenses for 2022 were $32.4 million, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results